Azapiron
Azapironi su klasa lekova koji se koriste kao anksiolitici i antipsihotici.[1][2][3][4] Oni se isto tako koriste kao zamena za antidepresive poput selektivnih inhibitora preuzimanja serotonina (SSRI).[5][6][7][8][9]
Reference uredi
- ↑ Eison AS (June 1990). „Azapirones: history of development”. Journal of Clinical Psychopharmacology 10 (3 Suppl): 2S–5S. PMID 1973936.
- ↑ Cadieux RJ (May 1996). „Azapirones: an alternative to benzodiazepines for anxiety”. American Family Physician 53 (7): 2349–53. PMID 8638511.
- ↑ Chessick CA, Allen MH, Thase M, et al. (2006). Chessick, Cheryl A. ur. „Azapirones for generalized anxiety disorder”. Cochrane Database of Systematic Reviews (Online) 3: CD006115. DOI:10.1002/14651858.CD006115. PMID 16856115.
- ↑ Feighner JP, Boyer WF (1989). „Serotonin-1A anxiolytics: an overview”. Psychopathology 22 Suppl 1: 21–6. PMID 2567039.
- ↑ Van Ameringen M, Mancini C, Wilson C (July 1996). „Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia”. Journal of Affective Disorders 39 (2): 115–21. DOI:10.1016/0165-0327(96)00030-4. PMID 8827420.
- ↑ Bouwer C, Stein DJ (April 1997). „Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression”. South African Medical Journal 87 (4 Suppl): 534–7, 540. PMID 9180827.
- ↑ Dimitriou EC, Dimitriou CE (December 1998). „Buspirone augmentation of antidepressant therapy”. Journal of Clinical Psychopharmacology 18 (6): 465–9. DOI:10.1097/00004714-199812000-00009. PMID 9864079.
- ↑ Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH (June 2001). „Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study”. The Journal of Clinical Psychiatry 62 (6): 448–52. DOI:10.4088/JCP.v62n0608. PMID 11465522.
- ↑ Yamada K, Yagi G, Kanba S (April 2003). „Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial”. Psychiatry and Clinical Neurosciences 57 (2): 183–7. DOI:10.1046/j.1440-1819.2003.01099.x. PMID 12667165.[mrtav link]